The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response

Vaccine

Volumn 29, Issue 45, 2011, Pages 8002-8011

  Seyoum, Beza ^a   Yano, Masahide ^a   Pirofski, Liise anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CXCR3; IFN inducible chemokines; Inflammation; Pneumococcal pathogenesis; Serotype 3 pneumococcus; Serotype 8 pneumococcus

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; CHEMOKINES; FEMALE; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEUTROPHILS; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 80053654363     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.064     Document Type: Article

References (48)

1. Huang S.S., Johnson K.M., Ray G.T., Wroe P., Lieu T.A., Moore M.R., et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011, 29(18):3398-3412.
2. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995, 33(October (10)):2759-2762.
3. Scott J.A.G., Hall A.J., Dagan R., Dixon J.M., Eykyn S.J., Fenoll A., et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease. Clin Infect Dis 1996, 22:973-981.
4. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(May (5)):e1000081.
5. Byington C.L., Hulten K.G., Ampofo K., Sheng X., Pavia A.T., Blaschke A.J., et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010, 48(February (2)):520-525.
6. Nuorti J.P., Whitney C.G. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(December (RR-11)):1-18.
7. Poolman J., Kriz P., Feron C., Di-Paolo E., Henckaerts I., Miseur A., et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009, 27(May (24)):3213-3222.
8. Sleeman K.L., Griffiths D., Shackley F., Diggle L., Gupta S., Maiden M.C., et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006, 194(September (5)):682-688.
9. Weinberger D.M., Harboe Z.B., Sanders E.A., Ndiritu M., Klugman K.P., Rückinger S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010, 51(September (6)):692-699.
10. Briles D.E., Crain M.J., Gray B.M., Forman C., Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 1992, 60(1):111-116.
11. Weber S.E., Tian H., Pirofski L.A. CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol 2011, 186(January (1)):432-442.
12. Marks M., Burns T., Abadi M., Seyoum B., Thornton J., Tuomanen E., et al. Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice. Infect Immun 2007, 75(April (4)):1586-1597.
13. Tian H., Weber S., Thorkildson P., Kozel T.R., Pirofski L.A. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun 2009, 77(April (4)):1502-1513.
14. Tian H., Groner A., Boes M., Pirofski L. Pneumococcal capsular polysaccharide vaccine-mediated protection of immunodeficient mice against serotype 3 Streptococcus pneumoniae. Infect Immun 2007, 75:1643-1650.
15. Fabrizio K., Groner A., Boes M., Pirofski L.A. A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection. Clin Vaccine Immunol 2007, 14(April (4)):382-390.
16. Coleman J.R., Papamichail D., Yano M., Garcia-Suarez M.M., Pirofski L.A. Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias. J Infect Dis 2011, 203(May (9)):1264-1273.
17. Giebink G.S., Verhoef G., Peterson P.K., Quie P.G. Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII and XXV. Infect Immun 1977, 18:291-297.
18. Fine D.P. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun 1975, 12:772-778.
19. Buchwald U.K., Pirofski L. Immune therapy for infectious diseases at the dawn of the 21(st) century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 2003, 9(12):945-968.
20. Munoz R., Mollerach M., Lopez R., Garcia E. Characterization of the type 8 capsular gene cluster of Streptococcus pneumoniae. J Bacteriol 1999, 181(October (19)):6214-6219.
21. Saksouk N., Pelosi L., Colin-Morel P., Boumedienne M., Abdian P.L., Geremia R.A. The capsular polysaccharide biosynthesis of Streptococcus pneumoniae serotype 8: functional identification of the glycosyltransferase WciS (Cap8H). Biochem J 2005, 389(July (Pt 1)):63-72.
22. Lock R.A., Zhang Q.Y., Berry A.M., Paton J.C. Sequence variation in the Streptococcus pneumoniae pneumolysin gene affecting haemolytic activity and electrophoretic mobility of the toxin. Microb Pathog 1996, 21(August (2)):71-83.
23. Sanz J.C., Cercenado E., Marin M., Ramos B., Ardanuy C., Rodriguez-Avial I., et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect 2011, 17(July (7)):1094-1098.
24. Domenech A., Ardanuy C., Calatayud L., Santos S., Tubau F., Grau I., et al. Serotypes and genotypes of Streptococcus pneumoniae causing pneumoia and acute exacerbations in patients with chronic obstructive pulmonary disease. J Antimicrob Chemother 2010.
25. Hancock W.W., Lu B., Gao W. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192(November (10)):1515-1520.
26. Yano M., Pirofski L. Characterization of the gene use and efficacy of mouse monoclonal antibodies to serotype 8 Streptococcus pneumoniae. Clin Vaccine Immunol 2011, 18:59-66.
27. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996, 184(September (3)):963-969.
28. Cole K.E., Strick C.A., Paradis T.J., Ogborne K.T., Loetscher M., Gladue R.P., et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC. chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998, 187(June (12)):2009-2021.
29. Joyce E.A., Popper S.J., Falkow S. Streptococcus pneumoniae nasopharyngeal colonization induces type I interferons and interferon-induced gene expression. BMC Genomics 2009, 10:404.
30. Rosseau S., Hocke A., Mollenkopf H., Schmeck B., Suttorp N., Kaufmann S.H., et al. Comparative transcriptional profiling of the lung reveals shared and distinct features of Streptococcus pneumoniae and influenza A virus infection. Immunol 2007, 120(March (3)):380-391.
31. McConnell K.W., McDunn J.E., Clark A.T., Dunne W.M., Dixon D.J., Turnbull I.R., et al. Streptococcus pneumoniae and Pseudomonas aeruginosa pneumonia induce distinct host responses. Crit Care Med 2010, 38(January (1)):223-241.
32. Zhang H., Su Y.A., Hu P., Yang J., Zheng B., Wu P., et al. Signature patterns revealed by microarray analyses of mice infected with influenza virus A and Streptococcus pneumoniae. Microbes Infect 2006, 8(July (8)):2172-2185.
33. Witzenrath M., Pache F., Lorenz D., Koppe U., Gutbier B., Tabeling C., et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 2011, 187(July):434-440.
34. Manicone A.M., Burkhart K.M., Lu B., Clark J.G. CXCR3 ligands contribute to Th1-induced inflammation but not to homing of Th1 cells into the lung. Exp Lung Res 2008, 34(September (7)):391-407.
35. Qin S., Rottman J.B., Myers P., Kassam M., Weinblatt M., Loetscher M., et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998, 101(February (4)):746-754.
36. Liu L., Callahan M.K., Huang D., Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 2005, 68:149-181.
37. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999, 5(August (8)):919-923.
38. Garcia-Lopez M.A., Sanchez-Madrid F., Rodriguez-Frade J.M., Mellado M., Acevedo A., Garcia M.I., et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 2001, 81(March (3)):409-418.
39. Gasperini S., Marchi M., Calzetti F., Laudanna C., Vicentini L., Olsen H., et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999, 162(April (8)):4928-4937.
40. Srivastava M., Jung S., Wilhelm J., Fink L., Buhling F., Welte T., et al. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J Immunol 2005, 175(August (3)):1884-1893.
41. Eliasson M., Morgelin M., Farber J.M., Egesten A., Albiger B. Streptococcus pneumoniae induces expression of the antibacterial CXC chemokine MIG/CXCL9 via MyD88-dependent signaling in a murine model of airway infection. Microbes Infect 2010, 12(July (7)):565-573.
42. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119(July (7)):1899-1909.
43. Knapp S., Leemans J.C., Florquin S., Branger J., Maris N.A., Pater J., et al. Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia. Am J Respir Crit Care Med 2003, 167(January (2)):171-179.
44. Ferreira D.M., Moreno A.T., Cianciarullo A.M., Ho P.L., Oliveira M.L., Miyaji E.N. Comparison of the pulmonary response against lethal and non-lethal intranasal challenges with two different pneumococcal strains. Microb Pathog 2009, 47(September (3)):157-163.
45. Dallaire F., Ouellet N., Bergeron Y., Turmen V., Gauthier M.C., Simard M., et al. Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia. J Infect Dis 2001, 184(August (3)):292-300.
46. Jackson L.A., Janoff E.N. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008, 47(November (10)):1328-1338.
47. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348(1747):1755.
48. LeMessurier K., Hacker H., Tuomanen E., Redecke V. Inhibition of T cells provides protection against early invasive pneumococcal disease. Infect Immun 2010, 78(December (12)):5287-5294.